Navigation Links
AstraZeneca and Abbott End License Agreement for the Development of CERTRIAD
Date:12/22/2010

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.  

A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on March 30, 2010.

The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.  

AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009.  In the United States, AstraZeneca is a $14.8 billion healthcare business.   

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015  The Burzynski Research Institute, Inc. (BRI) announced ... by the Department of Surgery at Kurume University ... have been published. The study, a randomized non-blinded ... as post-operative adjuvant therapy with and without Antineoplastons ... A total of 65 patients, ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... 2015 Over-the-counter healthcare costs can be ... a new survey of store brand over-the-counter products ... cold to diabetes, can offer significant savings for ... the Private Label Manufacturers Association, assembled a market ... those essential for treatment of pre-diabetes and diabetes. ...
Breaking Medicine Technology:OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Consumers can keep over-the-counter medicine affordable by using store brands 2
... 2011 Arecor Limited has entered ... Company to assess Arecor,s advanced protein formulation technologies ... biological-based drugs.  Under this agreement, Arecor will develop ... protein and peptide drug candidates developed by Lilly.  In ...
... 2011 For 64 years, The Elko ... northeast Nevada town of roughly 20,000, providing family-oriented ... pediatrics, surgical procedures and the treatment of ... latest in medical technology and equipment toward ...
Cached Medicine Technology:Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics 2MedInformatix' Practice Management and Electronic Medical Records Dramatically Speed Family Practice's Receivables, Reduce Operating Costs 2MedInformatix' Practice Management and Electronic Medical Records Dramatically Speed Family Practice's Receivables, Reduce Operating Costs 3
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... and analysis of the healthcare, regulatory and reimbursement landscape ... 2013 amounted to 316.1 million, having grown at a ... The country’s increasingly elderly population and corresponding increase in ... the growth of the pharmaceutical market, which was worth ...
(Date:3/27/2015)... 27, 2015 California’s ongoing worst ever ... Boston and the United States Northeast, are both manifestations ... global atmosphere is creating changes in the atmosphere’s “energy ... and former NASA researcher, speaking on the Sharon Kleyne ... not only a warmer and dryer global climate but ...
(Date:3/27/2015)... 27, 2015 Approximately 300 advocates ... Kids Coalition Lobby Day to lobby for physical ... Program (SHIP). Everlast Climbing was especially interested ... SF343/HF498 which would strengthen physical education programs by ... and other measures to strengthen physical education in ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Smile Brands ... providers of business support services to dental groups in ... an affiliated Castle Dental office in Hendersonville, ... Hendersonville, TN 37075, this new Castle Dental office provides ... receive the latest in comprehensive, quality dental care. Hendersonville ...
(Date:3/27/2015)... In light of two lawsuits that ... District Court, District of Massachusetts; and case number 2:15-cv-00709PD, ... Pennsylvania), the San Diego personal injury lawyers of The ... that they are available to investigate potential birth ... prescribed Zofran while pregnant and who gave birth to ...
Breaking Medicine News(10 mins):Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 2Health News:California Drought, Boston Blizzards Both Attributed to Global Climate Change Reports Climatologist to Fresh Water Advocate 3Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 2Health News:Castle Dental® Opens Its First Dental Office in Hendersonville, TN 3Health News:The Law Office of Melinda J. Helbock, A.P.C. Announces That It Is Now Accepting Case Reviews for Potential Zofran Birth Defect Lawsuits 2
... has been shown that the drug Rimonabant (Acomplia) ... patients keep weight off // . Supplementation with 20 ... decrease in body weight and waist circumference -- a ... HDL (good) cholesterol, triglycerides, and the prevalence of metabolic ...
... cholesterol (“bad” cholesterol) to below 100 milligrams per deciliter ... is safe and results in fewer cardiovascular events. ... took 10 milligrams of atorvastatin (Lipitor) a day to ... deciliter a day or lower. Then, half of the ...
... in Spain has focused on the increasing incidence of ... associated with an increased risk of cancer in the ... been proven to have disastrous effects on the fetus ... complications such as extra uterine pregnancy, or pregnancy resulting ...
... increased recommendations for daily calcium intake, largely from dairy ... promote healthy bones and prevent osteoporosis. But a report ... milk or other dairy products was not necessarily the ... at least 400 milligrams per day. ,Other ways ...
... Most viruses, including herpes, cause both active infections and also ... no immediate infection // but can strike again whenever resistance ... those infected. ,Based on findings of a recent study ... as a treatment for a form of the herpes virus ...
... from the bone-thinning disease osteoporosis may also be at ... in which people have a difficult time digesting wheat ... bone mineral density, or BMD, among patients with both ... thinning bones, but little study exists to suggest if ...
Cached Medicine News:
The microprocessor-controlled, Norm-O-Temp® total body hyperthermia water system provides effective heat therapy at less than half the cost of a hyper-hypothermia system....
The control unit manage patient temperatures during long complex surgical procedures to help achieve optimal clinical outcomes....
... T5002 has it's temperature set by ... by pressing a button. A green ... and a flashing amber LED indicates ... temperature. A red LED and an ...
The Cocoon Convective Warming Machine is lightweight, compact and easy to use....
Medicine Products: